NCT00711828 - Rituximab, Cyclophosphamide, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Low-Grade Follicular Lymphoma, Waldenstrom Macroglobulinemia, or Mantle Cell Lymphoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 31, 2008

Primary Completion Date

November 30, 2013

Study Completion Date

April 6, 2018

Conditions

Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid TissueNodal Marginal Zone LymphomaRecurrent Grade 1 Follicular LymphomaRecurrent Grade 2 Follicular LymphomaRecurrent Mantle Cell LymphomaRecurrent Small Lymphocytic LymphomaRefractory Chronic Lymphocytic LeukemiaSplenic Marginal Zone LymphomaWaldenstrom Macroglobulinemia

Interventions

DRUG

Bortezomib

Given IV

BIOLOGICAL

Rituximab

Given IV

DRUG

Cyclophosphamide

Given PO

DRUG

Dexamethasone

Given PO

OTHER

Questionnaire Administration

Complete a quality of life questionnaire (FACT/GOG neurotoxicity questionnaire, version 4.0)

OTHER

Quality-of-Life Assessment

Complete a quality of life questionnaire (FACT/GOG neurotoxicity questionnaire, version 4.0)

Trial Locations (2)

55905

Mayo Clinic, Rochester

85259

Mayo Clinic in Arizona, Scottsdale